Related resources and publications
Humanized ICP mouse and cell lines
Humanized PD-1/PD-L1 mouse and cell line
Humanized PD-1 & GITR mouse
T-cell engager
Assess toxicity with ICP
The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.
The humanized OX40 mouse model (hOX40) is developed by Knockin at the mouse OX40 locus, and expresses a fully humanized OX40 with a human extracellular, transmembrane and intracellular domain.
Anti-tumor efficacy and tumor-specific immunological memory were proven in MC38 and MB49 tumor models.
hOX40 and mOX40 expression on splenocytes activated with αCD3/αCD28 in presence of mIL-2. Kinetic of hOX40 and mOX40 expression on Treg, conventional CD4 and CD8 T cells. Results are expressed as mean±SD.
Splenic and LN-isolated T cells (CD8+) activated with αCD3/αCD28 and immobilized hOX40L or IgG-Fc. A) Representative histogram, and B) cell proliferation determined by CFSE dilution at day 4. C) mIFN-γ production measured by ELISA in culture supernatant at day 3. Results are expressed as mean±SD. Unpaired T test analyses (Mann-Whitney ** p<0.01, *** p<0.001).
Humanized ICP mouse and cell lines
Humanized PD-1/PD-L1 mouse and cell line
Humanized PD-1 & GITR mouse
T-cell engager
Assess toxicity with ICP
The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.
Let us know how we can help
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate